Pfizer Ltd

₹ 4,002 -0.23%
27 Jan - close price
About

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1]
It is the 3rd largest multinational pharmaceutical company in India.[2]

Key Points

Product Portfolio
Presently, the company sells ~150 different products across 15+ therapeutic areas viz. anti-allergic, anti-diabetic, anti-infectives, cardiovascular, gastrointestinal, neurology, pain, respiratory, vitamin/minerals, antibiotics, etc.[1][2]

  • Market Cap 18,306 Cr.
  • Current Price 4,002
  • High / Low 4,800 / 3,983
  • Stock P/E 34.7
  • Book Value 637
  • Dividend Yield 0.87 %
  • ROCE 29.2 %
  • ROE 23.3 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 118%

Cons

  • The company has delivered a poor sales growth of 5.84% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
567 538 502 515 595 593 535 749 636 676 550 593 637
403 405 393 329 392 397 409 463 447 481 384 401 406
Operating Profit 164 133 109 186 203 197 126 286 189 195 165 192 232
OPM % 29% 25% 22% 36% 34% 33% 24% 38% 30% 29% 30% 32% 36%
45 58 45 17 12 15 37 12 15 18 17 -118 213
Interest 3 2 4 3 5 4 4 2 2 2 4 4 3
Depreciation 25 25 28 27 28 27 27 27 27 27 34 27 26
Profit before tax 181 164 122 173 183 180 132 269 175 184 145 43 415
Tax % 15% 15% 16% 28% 28% 22% 24% 26% 18% 22% 13% 25% 25%
Net Profit 154 139 103 124 131 141 101 200 143 144 126 33 311
EPS in Rs 33.72 30.40 22.52 27.20 28.72 30.87 21.98 43.70 31.25 31.46 27.50 7.12 68.00
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
1,252 1,093 1,049 1,112 1,853 2,012 1,966 1,969 2,082 2,152 2,239 2,611 2,456
983 897 865 872 1,438 1,579 1,616 1,468 1,516 1,578 1,526 1,775 1,672
Operating Profit 270 197 184 239 414 433 350 501 566 574 712 836 784
OPM % 22% 18% 18% 22% 22% 22% 18% 25% 27% 27% 32% 32% 32%
89 92 519 109 44 97 232 114 167 183 81 63 130
Interest 2 2 2 1 2 1 2 1 2 11 15 11 13
Depreciation 12 10 8 8 250 58 63 66 71 103 109 115 114
Profit before tax 345 278 694 340 207 470 517 548 660 642 669 773 788
Tax % 34% 33% 27% 35% 66% 35% 35% 34% 35% 21% 26% 21%
Net Profit 226 185 503 221 70 305 337 360 429 509 498 613 613
EPS in Rs 75.85 61.86 168.62 74.01 15.26 66.67 73.62 78.71 93.79 111.29 108.77 133.90 134.08
Dividend Payout % 22% 20% 19% 486% 82% 22% 27% 25% 24% 297% 32% 26%
Compounded Sales Growth
10 Years: 9%
5 Years: 6%
3 Years: 8%
TTM: -2%
Compounded Profit Growth
10 Years: 13%
5 Years: 19%
3 Years: 13%
TTM: -10%
Stock Price CAGR
10 Years: 13%
5 Years: 12%
3 Years: -3%
1 Year: -11%
Return on Equity
10 Years: 16%
5 Years: 17%
3 Years: 19%
Last Year: 23%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
30 30 30 30 46 46 46 46 46 46 46 46 46
Reserves 1,134 1,275 1,665 629 1,927 2,118 2,373 2,637 2,966 3,350 2,347 2,819 2,870
0 0 0 0 2 2 2 2 2 2 63 39 40
223 277 365 318 638 722 840 1,004 926 1,007 810 997 875
Total Liabilities 1,386 1,582 2,060 977 2,614 2,888 3,261 3,690 3,940 4,405 3,266 3,901 3,831
36 31 26 20 944 925 902 950 886 973 894 869 823
CWIP 2 0 0 3 13 3 15 1 0 1 3 1 5
Investments 49 48 46 44 43 37 0 0 0 0 0 0 0
1,300 1,502 1,988 909 1,614 1,923 2,343 2,739 3,054 3,432 2,369 3,030 3,002
Total Assets 1,386 1,582 2,060 977 2,614 2,888 3,261 3,690 3,940 4,405 3,266 3,901 3,831

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
80 24 -16 132 113 345 329 332 98 323 427 667
57 278 626 103 68 -701 -250 -238 35 1,530 -469 -575
-86 -14 -43 -1,360 -1 -62 -83 -110 -110 -164 -1,571 -181
Net Cash Flow 51 288 567 -1,125 181 -417 -3 -17 23 1,690 -1,613 -88

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 29 47 49 57 32 26 20 29 30 29 18 17
Inventory Days 149 186 181 148 191 167 148 147 189 198 199 173
Days Payable 92 138 165 156 165 157 178 245 213 197 130 102
Cash Conversion Cycle 86 95 65 49 58 36 -10 -69 6 31 87 89
Working Capital Days 118 71 7 25 7 -9 -46 -57 -15 -7 13 -7
ROCE % 32% 23% 19% 29% 24% 22% 17% 21% 23% 20% 23% 29%

Shareholding Pattern

Numbers in percentages

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92
3.69 2.51 1.93 1.87 1.89 2.07 2.07 2.13 2.20 2.55 2.55 2.77
12.66 14.41 14.96 14.31 14.63 15.15 15.15 15.03 15.06 14.83 14.88 14.93
19.73 19.16 19.18 19.89 19.55 18.86 18.86 18.92 18.82 18.70 18.65 18.39

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents